United Therapeutics New Drug Application Declined Pending Inspection Issue
October 18 2021 - 6:43AM
Dow Jones News
By Matt Grossman
United Therapeutics Corp.'s Tyvaso drug application wasn't
approved by the Food and Drug Administration, but the issue cited
by the agency can be resolved in the coming months, the company
said Monday.
United Therapeutics had applied for Tyvaso's approval to treat
pulmonary arterial hypertension and pulmonary hypertension
associated with interstitial lung disease. The FDA declined the
application because of an open inspection issue at a third-party
facility that performs analytical testing, the company said.
"We are confident that the single deficiency identified in the
complete response will be resolved quickly and that Tyvaso DPI can
receive approval by the summer of 2022, if not earlier," United
Therapeutics Chairman and Chief Executive Martine Rothblatt
said.
Chief Operating Officer Michael Benkowitz said the Silver
Spring, Md.-based pharmaceutical company is standing by its goal of
reaching 25,000 patients on its products by the end of 2025.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
October 18, 2021 06:28 ET (10:28 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
United Therapeutics (NASDAQ:UTHR)
Historical Stock Chart
From Mar 2024 to Apr 2024
United Therapeutics (NASDAQ:UTHR)
Historical Stock Chart
From Apr 2023 to Apr 2024